Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

This document records responses to public comments on the MolDX EndoPredict Breast Cancer Gene Expression Test Local Coverage Determination (DL37311) and notes the comment and notice periods; it does not itself state clinical coverage criteria. For specific indications, limitations, documentation requirements, and frequency limits for EndoPredict testing, refer to LCD DL37311 (effective 2021-07-11).

"This document is a response to public comments on MolDX: EndoPredict Breast Cancer Gene Expression Test Local Coverage Determination DL37311; comment period 05/28/2020–07/12/2020; notice period beg..."

Sign up to see full coverage criteria, indications, and limitations.